EasyBlog

This is some blog description about this site

COPENHAGEN, NOVEMBER 14, 2016 – Worldwide we a see a need for action against AMR and AntibioTx is highly aware of something has to be done. The 10th Berlin Conference on Life Sciences takes place 24th February 2017. 
The conference will focus on the problems we face combating AMR; such as the need for new R&D and improve clinical, financial and approval pathway in order to safeguard healthcare in the future.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, SEPTEMBER 19, 2016 – A 28-day repeat dosing study in Göttingen minipigs concluded that proprietary formulations of ATx201 are well tolerated and leads to very low systemic exposure. BioAdvice, a leading GLP and GMP contract research organization located in Denmark, conducted the study. The outcome confirms previous studies suggestive of the favorable safety profile of ATx201.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, SEPTEMBER 06, 2016 – AntibioTx has been invited to present recent positive results with ATx201 at the ‘2nd Inflammatory Skin Disease Summit’ symposium in New York the 16-20th November 2016. 

The ‘2nd Inflammatory Skin Disease Summit’ is a symposium that directly addresses and describes new developments and therapies for key inflammatory skin diseases, such as psoriasis, atopic dermatitis and an increasing number of other inflammatory conditions. 

The main purpose of the symposium is to update practicing dermatologist, MD-scientists and researchers in the field of treating skin diseases. The Symposium will feature internationally recognized researchers and will provide new research within skin infections and guidelines for future treatments improving clinical outcomes for the patients.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, AUGUST 19, 2016 – Dr. Keith Bostian is a well-renowned figure within science of medicine and has extensive experience with biotechnology industry entrepreneurship and has had executive operating roles in companies financed by leading venture firms within biotechnology. 

Morten Sommer, CSO of AntibioTx commented: ”I’m looking very much forward to the collaboration with Dr. Keith Bostian and have strong confidence that Keith will further help to accelerate recent progress on our chemistry platform to develop new chemical entities for treatment of unmet medical needs”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, AUGUST 07, 2016 – Recent in vivo studies in mice documents the antibacterial properties of ATx201 and that they compare favorably to marketed products. The CSO of AntibioTx, Dr. Morten Sommer, said “ATx201 looks promising in numerous points such as treatment duration, de novo resistance and effectiveness against multi-drug resistant bacteria including MRSA. We strongly believe that ATx201 will be a valuable asset in treating microbiome related disorders”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News